IASO Bio, a leading biopharmaceutical company, will set up its Global Research Center and Global Production and Operation Center in the Waigaoqiao Free Trade Zone after it signed an agreement with Shanghai Waigaoqiao Free Trade Zone United Development Co Ltd to rent the latter’s 64,000-square-meter land.
It is one of the key introduction projects of Waigaoqiao to enhance its cell therapy industry.
Shanghai Waigaoqiao Free Trade Zone United Development Co Ltd owns property covering a total area of 2.7 million square meters, including office buildings, factory buildings, warehouses, shops and other supporting facilities.
IASO Bio is engaged in novel cell therapies for oncology and autoimmune diseases.
Cell therapy, also called cellular therapy, cell transplantation, is a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect. For example, by transplanting T-cells capable of fighting cancer cells via cell-mediated immunity in the course of immunotherapy, or grafting stem cells to regenerate diseased tissues.
IASO Bio plans to build a high-level team committed to developing and industrializing high-end cell therapy medicine and biological medical products.
Of note, it will build the largest and the most comprehensive GMP production line domestically in Waigaoqiao. GMP, or Good Manufacturing Practice, is a system rolled out by the World Health Organization to ensure that goods are consistently produced and controlled according to quality standards.
So far, more than 900 overseas and domestic biopharmaceutical enterprises and medical equipment companies have settled in Waigaoqiao, with the industry scale reaching 220 billion yuan (US$ 34.45 billion).
